Sanofi S.A.
Market Data Current As Of: September 12, 2026
Related Competitor Intelligence
Compare market positioning with top industry peers
Explore Sanofi
Core profile pages, annual revenue records, and related research hubs for this company.
Sanofi S.A.
Compare market positioning with top industry peers
Explore Sanofi
Core profile pages, annual revenue records, and related research hubs for this company.
Financial Performance
Revenue
$43.6B
Market Cap
$135.0B
Net Income
$7.8B
Employees
91,000
Sanofi is executing a focused, disciplined strategic transformation to become the leader in immunology and rare blood disorders. Under CEO Paul Hudson, the French pharmaceutical giant generated exactly $46.5 billion in revenue and maintains a $135.0 billion market cap with exactly 91000 employees. The financial narrative in 2026 is entirely defined by Dupixent's explosive global dominance; relying on its extraordinary IL-4/IL-13 blockbuster as its singular financial engine, Sanofi extracts wildly compounding sales by furiously expanding Dupixent's label into new indications (COPD, alopecia areata) while simultaneously divesting its commoditized consumer healthcare division to fund next-generation pipeline investment.
Revenue Trend Analysis
YoY Change
+6.2%
2-Year CAGR
+7.4%
Peak Year
2025
Trend
Consistent Growth
Sanofi S.A. has reported revenue across 3 fiscal years, compounding at +7.4% annually over 2 years. The most recent year saw a 6.2% increase versus the prior year. Revenue peaked in 2025 at $43.6B. Out of 2 reported periods, 2 showed growth and 0 showed a decline.
| Fiscal Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $43.6B | $7.8B | +6.2% |
| FY2024 | $41.1B | $5.6B | +8.6% |
| FY2023 | $37.8B | $5.4B | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
Sanofi S.A. reported approximately $46.5B in fiscal year 2025 with a team of 91,000 employees worldwide.
Sanofi S.A. strategically balances reinvestment into core R&D with operational cost discipline, focusing on workflow automation to expand operating margins in 2026.
Financial performance in Pharmaceuticals and Biotechnology is driven by steady cash generation and pricing power, enabling Sanofi S.A. to reinvest in high-return strategic initiatives.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Sanofi S.A. Revenue & Financials." CorpDigest, https://corpdigest.com/company/sanofi/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Sanofi S.A. reported $44B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/sanofi/financials" target="_blank" rel="noopener">CorpDigest — Sanofi S.A. financials</a></div>